Intravitreal dexamethasone implant in retinitis pigmentosa-related cystoid macular edema

Intravitreal dexamethasone implant in retinitis pigmentosa-related cystoid macular edema

Author Mansour, Ahmad M. Google Scholar
Sheheitli, Huda Google Scholar
Kucukerdonmez, Cem Google Scholar
Sisk, Robert A. Google Scholar
Moura, Raphael Autor UNIFESP Google Scholar
Moschos, Marilita M. Google Scholar
Lima, Luiz H. Autor UNIFESP Google Scholar
Al-Shaar, Laila Google Scholar
Fernando Arevalo, J. Google Scholar
Maia, Mauricio Autor UNIFESP Google Scholar
Foster, Robert E. Google Scholar
Kayikcioglu, Ozcan Google Scholar
Kozak, Igor Google Scholar
Kurup, Shree Google Scholar
Zegarra, Hernando Google Scholar
Gallego-Pinazo, Roberto Google Scholar
Hamam, Rola N. Google Scholar
Bejjani, Riad A. Google Scholar
Cinar, Esat Google Scholar
Erakgun, Ethem T. Google Scholar
Kimura, Alan Google Scholar
Teixeira, Anderson Google Scholar
Abstract Purpose: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. Methods: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. Results: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16-57) and mean follow-up of 15.5 +/- 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 +/- 0.38 (20/81) to 0.37 +/- 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (mu m) decreased from 506 +/- 288 mu m to 311.7 +/- 71.6 mu m (P < 0.001) and mean intraocular pressure increased from 15.7 +/- 2.3 mmHg to 19.8 +/- 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1-7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. Conclusion: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage.
Keywords cystoid macular edema
dexamethasone implant
intraocular pressure
retinitis pigmentosa
xmlui.dri2xhtml.METS-1.0.item-coverage Philadelphia
Language English
Date 2018
Published in Retina-The Journal Of Retinal And Vitreous Diseases. Philadelphia, v. 38, n. 2, p. 416-, 2018.
ISSN 0275-004X (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 416-
Access rights Closed access
Type Article
Web of Science ID WOS:000428735400030

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account